Who are MYL-1701P, a proposed biosimilar to Eylea's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/myl-1701p-a-proposed-biosimilar-to-eylea.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

MYL-1701P, a proposed biosimilar to Eylea — Competitive Intelligence Brief

MYL-1701P, a proposed biosimilar to Eylea (MYL-1701P, a proposed biosimilar to Eylea) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (fusion protein) / VEGF inhibitor / Biosimilar. Area: Ophthalmology.

phase 3 Monoclonal antibody (fusion protein) / VEGF inhibitor / Biosimilar VEGF-A, VEGF-B, PlGF (vascular endothelial growth factor and placental growth factor) Ophthalmology Biologic Live · refreshed every 30 min

Target snapshot

MYL-1701P, a proposed biosimilar to Eylea (MYL-1701P, a proposed biosimilar to Eylea) — Mylan Pharmaceuticals Inc. MYL-1701P is a biosimilar to aflibercept that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit pathological neovascularization in the eye.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MYL-1701P, a proposed biosimilar to Eylea TARGET	MYL-1701P, a proposed biosimilar to Eylea	Mylan Pharmaceuticals Inc	phase 3	Monoclonal antibody (fusion protein) / VEGF inhibitor / Biosimilar	VEGF-A, VEGF-B, PlGF (vascular endothelial growth factor and placental growth factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (fusion protein) / VEGF inhibitor / Biosimilar class)

Mylan Pharmaceuticals Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MYL-1701P, a proposed biosimilar to Eylea — Competitive Intelligence Brief. https://druglandscape.com/ci/myl-1701p-a-proposed-biosimilar-to-eylea. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab